Delivery Order SPE2DB22D3501-SPE2DB24FVN36

Award Date 5/3/24
Potential Completion Date 5/6/24
Potential Value $3.7K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of REXULTI 1 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distributor. The contract is a Delivery Order with a Firm Fixed Price type and has a ceiling value of $14,605.44 with a completion date of January 12, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award is for the delivery of REXULTI 2 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $7,056.20 and was awarded to the prime contractor, Amerisourcebergen Drug Corp, on May 21, 2024. The contract is a Firm Fixed Price Delivery Order and does not have a set-aside designation. Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, is a major supplier of pharmaceutical products and...
This federal contract award is for the delivery of REXULTI 1 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $3,478.90, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of November 19, 2024. The contract is not designated with a set-aside requirement, indicating open...
This federal contract award is for the delivery of REXULTI 0.5 MG TABLET 30S pharmaceutical products to the Defense Logistics Agency (DLA). The $6,034.90 firm-fixed-price delivery order was issued to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has an ultimate completion date of May 11, 2023 and was awarded on May 10, 2023. This contract is not set aside for any specific business type. Amerisourcebergen Drug Corp is a major pharmaceutical...
This federal contract award is for the delivery of REXULTI 1 MG TABLET 30S to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., for a ceiling value of $12,044.36. The contract is a firm fixed-price delivery order with a completion date of September 27, 2023. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
This federal contract award is for the delivery of REXULTI 1 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price of $1,831.84 and a completion date of December 20, 2024. This award is not associated with any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp...
This federal contract award is for the delivery of REXULTI 0.5 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $3,255.24 and was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., as the prime contractor. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the...
This federal contract award is for the delivery of REXULTI 2 MG TABLET 30S to the Defense Logistics Agency (DLA), a defense agency under the Department of Defense (DoD). The contract, valued at $5,725.72, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on June 20, 2024, with a completion date of June 21, 2024. The contract is a Delivery Order, with a Firm Fixed Price pricing structure. It is not designated as a set-aside contract. Amerisourcebergen Drug Corp's...
This federal contract award is for the delivery of REXULTI 0.5 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $4,576.81, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., on September 6, 2023, with a completion date of September 7, 2023. The contract is a Delivery Order with a Firm Fixed Price pricing type. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of REXULTI 0.5 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA) under a Firm Fixed Price Delivery Order. The contract has a ceiling value of $2,655.60 and a completion date of July 3, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB24FVN36
    Delivery Order

This federal contract award is for the delivery of REXULTI 0.5 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $3,739.30, was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., on May 3, 2024, with a completion date of May 6, 2024.

Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. This contract award is likely a delivery order placed under that larger IDC contract. The contract does not have a set-aside designation, indicating open competition.

Generated 5/16/25, 12:09 PM